Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 9:30 am GMT in London. Interested parties can access both the live webcast and replay of the presentation through the Investor Relations/Events section on the company’s website.
Arcturus Therapeutics (Nasdaq: ARCT), un’azienda commerciale di medicinali a mRNA specializzata in vaccini per malattie infettive e malattie rare del fegato e delle vie respiratorie, ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference. La presentazione è programmata per mercoledì 20 novembre 2024, alle 9:30 GMT a Londra. Le parti interessate possono accedere sia al webcast in diretta sia alla registrazione della presentazione attraverso la sezione Relazioni con gli Investitori/Eventi sul sito web dell’azienda.
Arcturus Therapeutics (Nasdaq: ARCT), una empresa comercial de medicamentos de ARN mensajero especializada en vacunas para enfermedades infecciosas y enfermedades raras del hígado y respiratorias, ha anunciado su participación en la Jefferies London Healthcare Conference. La presentación está programada para miércoles 20 de noviembre de 2024, a las 9:30 a.m. GMT en Londres. Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición de la presentación a través de la sección de Relaciones con Inversores/Eventos en el sitio web de la empresa.
Arcturus Therapeutics (Nasdaq: ARCT), 감염병 백신과 간 및 호흡기 희귀 질환에 전문화된 상업 mRNA 의약품 회사가 제퍼리즈 런던 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 발표는 2024년 11월 20일 수요일, GMT 오전 9시 30분에 런던에서 예정되어 있습니다. 관심 있는 분들은 회사 웹사이트의 투자자 관계/이벤트 섹션을 통해 실시간 웹캐스트와 발표 다시보기를 모두 확인할 수 있습니다.
Arcturus Therapeutics (Nasdaq: ARCT), une entreprise commercialisant des médicaments à base d’ARNm spécialisée dans les vaccins contre les maladies infectieuses et les maladies rares du foie et des voies respiratoires, a annoncé sa participation à la Jefferies London Healthcare Conference. La présentation est prévue pour mercredi 20 novembre 2024, à 9h30 GMT à Londres. Les parties intéressées peuvent accéder à la fois à la diffusion en direct et au replay de la présentation dans la section Relations Investisseurs/Événements du site Web de l’entreprise.
Arcturus Therapeutics (Nasdaq: ARCT), ein kommerzielles Unternehmen für mRNA-Arzneimittel, das sich auf Impfstoffe gegen Infektionskrankheiten sowie auf seltene Erkrankungen der Leber und der Atemwege spezialisiert hat, hat seine Teilnahme an der Jefferies London Healthcare Conference angekündigt. Die Präsentation ist für Mittwoch, den 20. November 2024, um 9:30 Uhr GMT in London angesetzt. Interessierte Parteien können sowohl auf das Live-Webcast als auch auf die Wiederholung der Präsentation über den Bereich Investor Relations/Events auf der Unternehmenswebsite zugreifen.
SAN DIEGO–(BUSINESS WIRE)– Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.
A webcast and replay of the presentation will be available on the Investor Relations/Events section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar.
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241118497441/en/
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of Investor Relations/PR & Marketing
(858) 900-2682
Source: Arcturus Therapeutics Holdings Inc.
FAQ
When is Arcturus Therapeutics (ARCT) presenting at the Jefferies London Healthcare Conference 2024?
Arcturus Therapeutics will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 am GMT in London.
How can investors watch Arcturus Therapeutics’ (ARCT) Jefferies Conference presentation?
Investors can watch the presentation through a webcast available on the Investor Relations/Events section of Arcturus’ website at https://ir.arcturusrx.com/investor-calendar.
What is the main business focus of Arcturus Therapeutics (ARCT)?
Arcturus Therapeutics is a commercial mRNA medicines company focused on developing infectious disease vaccines and treatments for liver and respiratory rare diseases.
Will there be a replay available for Arcturus Therapeutics’ (ARCT) Jefferies Conference presentation?
Yes, a replay of the presentation will be available on the Investor Relations/Events section of the company’s website.
